Mosaic Therapeutics closes $28m series A funding and appoint

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP appointed as CEO to drive growth ambitions Mosaic Therapeuti

Related Keywords

Japan , Cambridge , Cambridgeshire , United Kingdom , Netherlands , Australia , South Korea , Magdalena Jonikas , Adrian Ibrahim , Emile Voest , Brian Gladsden , Mathew Garnett , Partner At Syncona Investment Management , Syncona Investment Management Ltd , Mosaic Therapeutics Ltd , Netherlands Cancer Institute , Worldwide Leadership Team , Head Of Technology Translation , Bayer Ag , Dr Mathew Garnett Translational Cancer Genomics Laboratory , Loncode Institute , Wellcome Sanger Institute , Group Leader , Senior Group Leader At Sanger , Netherlands Cancer , Cambridge Innovation Capital , Novartis Oncology , Syncona Investment Management , Cambridge Innovation , Senior Vice President , Translational Cancer Genomics Laboratory , Wellcome Sanger , Senior Group Leader , Werner Syndrome , Mosaic Therapeutics , Professor Emile Voest , Professor Voest , Medical Oncology , Cancer Core Europe , Independent Director , Technology Translation , Lead Partner , Syncona Investment Management Limited ,